(VIANEWS) – Shares of OXURION (BEL 20: OXUR.BR) dropped by a staggering 29.08% in 21 sessions from 0.03 € to 0.02 € at 19:25 EST on Thursday, after five successive sessions in a row of losses. BEL 20 is jumping 0.52% to 3,922.01 €, following the last session’s upward trend.
OXURION’s last close was 0.01 €, 99.28% under its 52-week high of 1.95 €.
About OXURION
Oxurion NV, a biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases in Belgium and internationally. Its lead product is JETREA for the treatment of vitreomacular adhesion/vitreomacular traction. The company also develops THR-149, a plasma kallikrein inhibitor, which is in Phase II clinical trials for the treatment of diabetic macular edema (DME); and THR-687, an integrin antagonist which is in Phase II clinical trials for the treatment of DME. It has collaboration agreements with Bicycle Therapeutics, INC Research, and Galapagos NV. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.
Earnings Per Share
As for profitability, OXURION has a trailing twelve months EPS of -0.732 €.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -694.15%.
Volatility
OXURION’s last week, last month’s, and last quarter’s current intraday variation average was a negative 9.15%, a negative 4.13%, and a positive 12.98%.
OXURION’s highest amplitude of average volatility was 9.15% (last week), 6.86% (last month), and 12.98% (last quarter).
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, OXURION’s stock is considered to be overbought (>=80).
Revenue Growth
Year-on-year quarterly revenue growth declined by 21.9%, now sitting on 1.05M for the twelve trailing months.
More news about OXURION (OXUR.BR).
